Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism

American Journal of Kidney Diseases

Volumn 32, Issue 2, 1998, Pages 238-246

  Akiba, Takashi ^a   Marumo, Fumiaki ^b   Owada, Akira ^b   Kurihara, Satoshi ^b   Inoue, Atsushi ^b   Chida, Yoshiko ^b   Ando, Ryoichi ^b   Shinoda, Toshio ^b   Ishida, Yuji ^b   Ohashi, Yasuo ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Alfacalcidol; Crossover trial; Falecalcitriol; Parathyroid hormone (PTH); Secondary hyperparathyroidism

Indexed keywords

ALFACALCIDOL; FALECALCITRIOL; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTRITIS; HEART ARRHYTHMIA; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPERTENSION; INSOMNIA; MALE; PARATHYROID HORMONE BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM;

EID: 13144251144     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9708607     Document Type: Article

References (19)

1. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin K: Marked suppression of hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143, 1984
2. Silver J, Russell J, Sherwood LM: Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 82:4270-4273, 1985
3. 3. Chem Pharm Bull 30:4297-4303, 1982
4. Komuro S, Kanamaru H, Nakatsuka I, Yoshitake A: Disposition and metabolism of ST-630 (2): Metabolism after single administration of 3H-ST-630 in rats. Xenobio Metabol Dispos 11:518-529, 1996
5. Katsumata T, Tanaka T, Ishibashi E, Nakatsuka M: The biological activity of ST-232, the main metabolite of falecalcitriol. Kisoto Rinsyou (Japan) 30:2991-2996, 1996
6. 3. Arch Biochem Biophys 229:348-354, 1984
7. Payne RB, Littel AJ, Williams RB, Milner JR: Adjustment of plasma calcium measurement. Br Med J 4:643-646, 1973
8. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 57:23-28, 1991
9. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G, on behalf of the Italian Group for the Study of Intravenous Calcitriol: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Kidney Int 421:1191-1198, 1992
10. Rothmund M: Surgical treatment of secondary hyper-parathyroidism: Indication, operative management and results. Prog Surg 18:186-205, 1986
11. Brown AJ, Ritter CR, Finch LJ, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E: The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 84:728-732, 1989
12. 2, suppresses parathyroid hormone in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 26:852-860, 1995
13. Tan AU Jr., Levine BS, Mazess RB, Kyllo DM, Bishop CW, Knutson JC, Kleinman KS, Coburn JW: Effective suppression of parathyroid hormone by 1a-hydroxyvitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 51:317-323,1997
14. 3 Research Committee, Japan: Effect of hexafluorocalcitriol on renal osteodystrophy in hemodialysed patients. Nephrol Dial Transplant 11:1204, 1996 (abstr)
15. 3 on mineral metabolism in man. I. Effects on net absorption of phosphorus. Am J Clin Nutr 30:1064-1069, 1977
16. Morii H, Koshikawa S, Mimura N, Ogura Y, Suzuki M, Kurokawa K, Kawaguchi Y, Nishizawa Y, Inoue S, Suzuki Y, Maeda K, Fujimi S: Clinical efficacy and optimal dose of ST-630 (falecalcitriol) in secondary hyperparathyroid-ism in patients undergoing hemodialysis: Late Phase II multicenter trial. J Jpn Soc Dial Ther 30:895-910, 1997
17. Morii H, Ogura Y, Koshikawa S, Mimura N, Suzuki M, Kurokawa K, Marumo F, Kawaguchi Y, Maeda K, Nishizawa Y, Inoue S, Fujimi S: Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialy-sis patients with secondary hyperparathyroidism. J Bone Miner Metab 16:34-43, 1998
18. Tsushima N, Katsumata T, Ishibashi E, Negoro H, Nakatsuka T: Therapeutic effects of falecalcitriol on secondary hyperparathyroidism and osteodystrophy in 5/6 nephrectomized rats. Kito to Rinsyou (Japan) 30:2963-2974, 1996
19. Sasaki H, Harada H, Handa Y, Morino H, Suzuwa M, Shimpo E, Katsumata T, Masuhiro Y, Matsuda K, Ebihara K, Ono T, Masushige S, Kato S: Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. Biochemistry 34:370-377, 1995